Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06208033

SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

EGFR Positive Non-small Cell Lung Cancer Clinical Trial

Official title:
A Single-arm, Sequential Study Assessing the Efficacy and Safety of SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC) : First-line Treatment or Failed From First-line Immune Checkpoint Inhibitor Treatment.

Clinical Trial Summary

This is a single-arm, sequential study assessing the efficacy and safety of SMET12 and Toripalimab combined chemotherapy in patients with EGFR positive advanced non-small cell lung cancer (NSCLC) : first-line treatment or failed from first-line immune checkpoint inhibitor treatment.The primary objective is to evaluate the anti-tumor activity and safety of SMET12 and Toripalimab combined chemotherapy in patients with EGFR positive advanced NSCLC.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06208033
Study type Interventional
Source Fujian Cancer Hospital
Contact Zhiyong He
Phone +86 138 0508 6391
Email heyong1015@163.com
Status Not yet recruiting
Phase Early Phase 1
Start date January 10, 2024
Completion date December 30, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02125240 - Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma Phase 3
Active, not recruiting NCT04027647 - Phase 2 Study of Dacomitinib in NSCLC Phase 2
Not yet recruiting NCT04643847 - A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases Phase 2
Active, not recruiting NCT03126799 - A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+) Phase 2
Recruiting NCT04900935 - Patient-centered, Optimal Integration of Survivorship and Palliative Care N/A
Not yet recruiting NCT02788058 - A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy Phase 2
Recruiting NCT02103257 - Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Phase 4
Recruiting NCT05338619 - A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy Phase 2
Recruiting NCT05037331 - Osimertinib for Advanced EGFR-positive NSCLC Patients
Recruiting NCT04001777 - A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients Phase 1
Active, not recruiting NCT02194556 - Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC Phase 4
Active, not recruiting NCT03382795 - Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients Phase 2
Recruiting NCT05089916 - Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study Phase 2
Completed NCT02729298 - First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT01665417 - Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Phase 4
Not yet recruiting NCT05962021 - Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation Phase 2
Completed NCT04105153 - Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC